BeiGene Plans to Raise up to $2.5 Billion in Shanghai Star IPO

BeiGene (NSDQ: BGNE; HK: 06160) is planning an IPO on the Shanghai Star Exchange that could raise up to $2.5 billion. The Beijing company is already listed in Hong Kong and the US , and it raised $2.1 billion in a secondary offering on the Hong Exchange in July of this year. Now ten years old, BeiGene is spending big to conduct clinical trials for drug approvals and additional indications for its products. At the end of Q3, the company has $4.7 billion of cash in hand, but it lost $560 million in the first nine months of 2020 on revenues totaling $371 million. More details.... Stock Symbols: (NSDQ: BGNE; HK: 06160) Share this with colleagues: // //